DavidMichelsonMD

PubMed

• Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
  Egan, M. F.,Kost, J.,Voss, T.,Mukai, Y.,Aisen, P. S.,Cummings, J. L.,Tariot, P. N.,Vellas, B.,van Dyck, C. H.,Boada, M.,Zhang, Y.,Li, W.,Furtek, C.,Mahoney, E.,Harper ...> ;N. Engl. J. Med.. 2019 Apr 11
• Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
  Herring, W. J.,Connor, K. M.,Snyder, E.,Snavely, D. B.,Morin, C. M.,Lines, C.,Michelson, D.> ;Sleep Med.. 2018 Dec 14
• 15 citations
  Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.
  Kathryn M. Connor, Paulette Ceesay, Jill Hutzelmann, Duane B. Snavely, Andrew D. Krystal, Madhukar H. Trivedi, Michael E. Thase, Christopher Lines, W. Joseph Herring> ;The International Journal of Neuropsychopharmacology. 2017 Aug 1
• Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
  Stocchi, F.,Rascol, O.,Hauser, R. A.,Huyck, S.,Tzontcheva, A.,Capece, R.,Ho, T. W.,Sklar, P.,Lines, C.,Michelson, D.,Hewitt, D. J.> ;Neurology. 2017 May 12
• Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
  Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D> ;J Clin Sleep Med. 2016-09-15
• A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.
  Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ> ;Int. J. Neuropsychopharmacol.. 2016-08-01
• Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
  Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, Herring WJ> ;Sleep Med.. 2016-03-01
• At a Crossroads: A Perspective on Drug Development for Alzheimer's Disease in 2016.
  Michelson, D.,Egan, M.> ;J Prev Alzheimers Dis. 2016 Jan 01
• Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
  Hauser, R. A.,Stocchi, F.,Rascol, O.,Huyck, S. B.,Capece, R.,Ho, T. W.,Sklar, P.,Lines, C.,Michelson, D.,Hewitt, D.> ;JAMA Neurol. 2015 Nov 03
• Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis.
  Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D> ;Cephalalgia. 2015-04-01
• Suvorexant in Patients with Insomnia: Results from Two 3-Month Randomized Controlled Clinical Trials.
  Herring, W. J.,Connor, K. M.,Ivgy-May, N.,Snyder, E.,Liu, K.,Snavely, D. B.,Krystal, A. D.,Walsh, J. K.,Benca, R. M.,Rosenberg, R.,Sangal, R. B.,Budd, K.,Hutzelmann, J...> ;Biol. Psychiatry. 2014 Dec 21
• 183 citations
  Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
  Tony W. Ho, Kathryn M. Connor, Ying Zhang, Eric Pearlman, Janelle Koppenhaver, Xiaoyin Fan, Christopher Lines, Lars Edvinsson, Peter J. Goadsby, David Michelson> ;Neurology. 2014 Sep 9
• Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-con...
  Michelson, D.,Snyder, E.,Paradis, E.,Chengan-Liu, M.,Snavely, D. B.,Hutzelmann, J.,Walsh, J. K.,Krystal, A. D.,Benca, R. M.,Cohn, M.,Lines, C.,Roth, T.,Herring, W. J.> ;Lancet Neurol. 2014 Apr 01
• Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure the...
  Herring, W. J.,Liu, K.,Hutzelmann, J.,Snavely, D.,Snyder, E.,Ceesay, P.,Lines, C.,Michelson, D.,Roth, T.> ;Sleep Med.. 2013 Oct
• 29 citations
  Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.
  Michael F. Egan, Xin Zhao, Andrew Smith, Matthew D. Troyer, Victor N. Uebele, Valerii Pidkorytov, Kevin Cox, Michael F. Murphy, Duane B. Snavely, Christopher Lines, Da...> ;Human Psychopharmacology. 2013 Mar 1
• Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
  F Egan, M.,Zhao, X.,Gottwald, R.,Harper-Mozley, L.,Zhang, Y.,Snavely, D.,Lines, C.,Michelson, D.> ;Schizophr. Res.. 2013 May
• Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.
  Michelson, D.,Hargreaves, R.,Alexander, R.,Ceesay, P.,Hietala, J.,Lines, C.,Reines, S.> ;Int J Neuropsychopharmacol. 2013 Feb
• Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs.
  Hewitt, D. J.,Pearlman, E.,Hämäläinen, M.,Lewis, D.,Connor, K. M.,Michelson, D.,Ceesay, P.,Assaid, C.,Bachman, R.,Harper Mozley, L.,Dupre, N.,Strickler, N.,Mahoney, E....> ;Headache. 2013 Jan
• Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
  Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D> ;Neurology. 2012-12-04
• Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.
  Herring WJ, Wilens TE, Adler LA, Baranak C, Liu K, Snavely DB, Lines CR, Michelson D> ;J Clin Psychiatry. 2012-07-01
• 59 citations
  Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment ...
  Tony W. Ho, Eric Pearlman, Donald W. Lewis, Mirja Hämäläinen, Kathryn M. Connor, David Michelson, Ying Zhang, Christopher Assaid, Lyn Harper Mozley, Nancy Strickler, R...> ;Cephalalgia. 2012 Jun 18
• Pilot Randomized Controlled Study of a Histamine Receptor Inverse Agonist in the Symptomatic Treatment of AD.
  Egan, M., Yaari, R., Liu, L., Ryan, M., Peng, Y., Lines, C., Michelson, D.> ;Curr Alzheimer Res. 2012 May
• Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain.
  Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, Michelson D, Bolognese J, Alon A, Rosenberg E, Herman G, Wang H> ;Pain. 2011-03-01
• Challenges in analgesic drug development.
  Hewitt DJ, Hargreaves RJ, Curtis SP, Michelson D> ;Clin. Pharmacol. Ther.. 2009-10-01
• 3 citations
  Depression: Body and Brain
  > ;Biological Psychiatry. 2009 Sep 1
• Join now to see all